Earnings | Aarti Drugs Ltd. (NSE: AARTIDRUGS): Q4FY23 Results Out; Total Income rise 8.5% YoY

Aarti Drugs Ltd. is an Indian pharmaceutical company that specializes in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), intermediates, and formulations. The company has a global presence and exports its products to more than 60 countries. Aarti Drugs has a strong focus on research and development and has invested significantly in building state-of-the-art facilities and processes to ensure the highest quality of its products. The company has also received several awards and certifications for its commitment to quality and sustainability. In recent years, Aarti Drugs has expanded its portfolio to include products in the areas of anti-cancer, anti-inflammatory, and anti-diabetic therapies. The company has also made strategic acquisitions to enhance its capabilities and offerings. Overall, Aarti Drugs is well-positioned to capitalize on the growing demand for high-quality pharmaceutical products in both domestic and international markets.

• Aarti Drugs Ltd. reported Total Income for Q4 FY23 of ₹697 Crore up from ₹642 Crore year on year, a growth of 8.5%.
• Total Expenses for Q4 FY23 of ₹628 Crore up from ₹575 Crore year on year, a growth of 9.2%.
• Consolidated Net Profit of ₹53 Crore, up 0 % from ₹53 Crore in the same quarter of the previous year. 
• The Earnings per Share is ₹5.74, up 0.35 % from ₹5.72 in the same quarter of the previous year.